HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $51 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $51 price target.
August 08, 2023 | 10:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $51.
The 'Buy' rating from HC Wainwright & Co. indicates a positive outlook for Arcturus Therapeutics. The maintained price target of $51 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100